| Biotechnology Industry | Healthcare Sector | Ms. Xiujie Zhang CEO | SSE Exchange | CNE100005Q14 ISIN |
| CN Country | 404 Employees | 16 Jun 2026 Last Dividend | - Last Split | - IPO Date |
Innovita Biological Technology Co., Ltd., founded in 2006 and headquartered in Beijing, China, specializes in the research and development, manufacturing, marketing, and sales of POCT (Point of Care Testing) rapid diagnostic products. The company focuses on providing quick and accurate diagnostic solutions for a wide range of medical needs, including infectious diseases, outpatient emergencies, and health checks related to pregnancy and chronic diseases.
This service provides rapid diagnosis for a variety of pathogens, helping in the quick identification and management of infectious diseases.
Recognizing the complexity of co-infections, Innovita offers services for the joint detection of multiple pathogens, streamlining the diagnostic process for illnesses that may exhibit overlapping symptoms.
Designed for emergency and outpatient settings, this service facilitates the rapid diagnosis of conditions, ensuring timely treatment and intervention.
In response to the global pandemic, Innovita provides reliable and swift testing solutions for the detection of the coronavirus, aiding in controlling the spread of the virus.
Focusing on one of the most common health concerns, Innovita offers diagnostic testing for a range of respiratory infections, supporting the effective treatment of these ailments.
Innovita's pregnancy testing products offer quick, accurate results for early detection, providing essential information for expectant mothers.
Offering rapid detection tests for different types of hepatitis virus, Innovita plays a critical role in the early diagnosis and management of this serious liver disease.
This testing service is aimed at identifying enterovirus infections, which are common in children and can lead to various health issues.